Clinical Trial

A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open-label, dose-escalation and cohort expansion study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant protein) combine with IMM01(Anti-CD47 Recombinant Protein) in patients with advanced solid tumors who have received at least first line treatment in past.
Trial Details
NCT Number NCT07170787
Lead Sponsor ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Conditions Advanced Solid Tumors
Enrollment 104 participants
Start Date 2025-10-15
Primary Completion 2029-02 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2025-09-12